MedTrace Logo

Post C-Section Pain Control Using EXPAREL

NCT03377595 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-05-18

No results posted yet for this study

Summary

Evaluating the safety and efficacy of EXPAREL (Liposomal Bupivacaine ) for pain control in patients undergoing scheduled cesarean section by giving it either as infiltration in Transversus Abdominis Plane after finishing the procedure or through wound infiltration into the fascia prior to closure of skin

Conditions

  • Pain, Postoperative

Interventions

DRUG

Exparel

TAP (Transversus Abdominis Plane) block

DRUG

Exparel

Wound infiltration

Sponsors & Collaborators

Principal Investigators

  • Hiba Mustafa, MD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-02
Primary Completion
2019-08-30
Completion
2019-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03377595 on ClinicalTrials.gov